ClinicalTrials.gg
Not yet recruitingNCT07269769Updated Apr 8, 2026

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD

A Phase 3 interventional study of Sanhuang Jingshiming/Pills placebo in AMD, sponsored by Tasly Pharmaceutical Group Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Study summary

The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.

02

Conditions studied

  • AMD
03

In context

Lead sponsor

Tasly Pharmaceutical Group Co., Ltd is the lead sponsor of 32 studies on the registry; 17 are open to participants now.

First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 50 to 85 years old (inclusive of 50 and 85 years old)
  2. Meets the Western medical diagnostic criteria for neovascular age-related macular degeneration
  3. Meets the TCM syndrome differentiation criteria for Qi-Yin Deficiency with Phlegm-Blood Stasis Intermingling Syndrome
  4. The study eye is diagnosed with nAMD and the disease is in the active phase
  5. BCVA of the study eye assessed by the ETDRS visual acuity chart ranges from 25 to 78 letters
  6. Voluntarily participates in the clinical trial, signs the ICF, and is able to understand and comply with the trial procedures

Exclusion criteria

Exclusion Criteria:

  1. The study eye is complicated with pathologic myopia, high myopia, or secondary MNV caused by other definite diseases, glaucoma, diabetic retinopathy , retinal artery/vein occlusion , optic neuropathy (optic neuritis, optic atrophy, papilledema), macular hole, acute phase of intraocular inflammation, or other ocular diseases
  2. Patients with pure PED in the study eye
  3. Patients with subfoveal structural destruction or subfoveal fibrosis/scars/RPE tear/GA in the study eye
  4. Patients whose FP of the study eye shows a total macular lesion area > 9 disc areas (total lesion area is defined as the sum of the areas of MNV, atrophy, scars, and fibrosis); or patients whose FP of the study eye shows a maximum macular hemorrhage area > 4 disc areas
  5. Patients with CRT ≥ 700 μm in the study eye as assessed by OCT
  6. Patients with opaque refractive media (e.g., vitreous hemorrhage, cataract) in the study eye precluding adequate visualization of the fundus, or with a history of vitrectomy
  7. Patients planning to undergo any intraocular surgery on the study eye during the trial period
  8. Patients who received pharmacologic treatment for nAMD within 2 weeks prior to randomization
  9. Patients who received intravitreal anti-vascular endothelial growth factor therapy on the study eye within 4 months prior to randomization
  10. Patients who received photodynamic therapy , laser photocoagulation, macular surgery, transpupillary thermotherapy , or therapy on the study eye within 6 months prior to randomization
  11. Patients who underwent any intraocular or periocular surgery (excluding eyelid surgery) on the study eye within 3 months prior to randomization
  12. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg while on regular antihypertensive medication)
  13. History of major cardiovascular or cerebrovascular diseases, including but not limited to: ① history of myocardial infarction (MI), coronary angioplasty or bypass surgery, valvular heart disease or valvular repair, and treatment-requiring arrhythmia, unstable angina, (TIA), cerebrovascular accident (CVA), etc., within 6 months prior to randomization; ② congestive heart failure (CHF) with (NYHA) classification of Grade Ⅲ or Ⅳ
  14. Laboratory test abnormalities as follows: ① count ≤ 100 × 10⁹/L; ② (INR) ≥ 1.5; ③ total (TBIL) > 2 × (ULN); ④ (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN; ⑤ serum creatinine (Scr) > 1.5 × ULN
  15. Patients with severe and unstable diseases of the mental, neurological, respiratory, digestive, renal, metabolic, immune, hematologic, or other systems, as well as malignant tumors, who are assessed by the investigator as unsuitable for participation in this clinical trial
  16. Presence of any listed in the package insert of ranibizumab injection (Lucentis®) or other anti-VEGF injections
  17. Suspected allergy to any study drug
  18. Pregnant or lactating females; males or females who plan to conceive within 30 days from signing the ICF to the end of the trial, or who cannot use effective measures
  19. Participation in another interventional clinical trial within 3 months prior to randomization
  20. Other reasons deemed unsuitable for participation in this clinical trial by the investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Sanhuang Jingshiming Pills,1 sachet/dose, bid

    Drug: Sanhuang Jingshiming/Pills placebo

  • Placebo comparator
    Placebo Group

    Placebo,1 sachet/dose, bid

    Drug: Sanhuang Jingshiming/Pills placebo

Interventions

  • DrugSanhuang Jingshiming/Pills placebo

    Ranibizumab: 1 dose/study eye (Screening/Baseline), then PRN injections

    Also known as: Ranibizumab

06

What researchers measure

Primary outcomes

  1. Proportion of participants with ranibizumab injections

    Time frame: 24 weeks

Secondary outcomes

  1. Mean number of ranibizumab injections

    Time frame: 24 weeks

  2. Mean days between second ranibizumab injection and baseline

    Time frame: 24 weeks

  3. Change in BCVA from baseline

    Time frame: 24 weeks

  4. Proportion of participants with BCVA decrease ≥5/≥10/≥15 letters

    Time frame: 24 weeks

  5. Change in lesion site thickness

    Time frame: 24 weeks

  6. Change in CRT from baseline

    Time frame: 24 weeks

  7. Proportion of participants with new macular hemorrhage

    Time frame: 24 weeks

  8. Change in maximum macular hemorrhage area

    Time frame: 24 weeks

  9. Change in NEI VFQ-25 score from baseline

    The Visual Function Questionnaire 25(NEI VFQ-25) has a maximum score of 100 and a minimum score of 0. The higher the score, the better vision.

    Time frame: 24 weeks

  10. Change in TCM syndrome score from baseline

    There are a total of 5 projects in Traditional Chinese Medicine syndrome scale. The scale has a maximum score of 15 and a minimum score of 0. The higher the score, the more severe the disease.

    Time frame: 24 weeks

  11. Change in individual TCM syndrome score items from baseline

    There are a total of 5 projects in Traditional Chinese Medicine syndrome scale. which 2 primary symptoms scored from 0 to 6 points,and 3 secondary symptoms scored from 0 to 1 point. The higher the score, the more severe the disease.

    Time frame: 24 weeks

  12. Proportion of participants by TCM syndrome efficacy

    (clinical cure/marked effect/effective/ineffective)

    Time frame: 24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Dec 2031, 68 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 8, 2025
StartEst.
Apr 30, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2031
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07269769
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Apr 30, 2026 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Apr 8, 2026

Study contacts

Rui Liu
Contact
liurui383@taslypharma.com
022-86343626

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion